Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism

REDWOOD CITY, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today

Related Keywords

Stephanie Carrington ,Nevan Charles Elam ,Rezolute Inc ,Nasdaq ,Securities Exchange ,European Medicines Agency ,Chief Executive Officer ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Risk Factors ,Annual Report ,Quarterly Reports ,Region ,